Abstract: Described herein are novel PRMT5 inhibitors of Formula I and pharmaceutically acceptable salts thereof, as well as the pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity and may have use in treating proliferative, metabolic and blood disorders.

Abstract: Described herein are compounds of Formula (I) and pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity and may have use in treating proliferative, such as cancer, metabolic and blood disorders. Compounds of Formula (I) have the following structure of Formula (I).

Abstract: The present invention includes an intra-bronchial device, system, and method for providing a therapeutic agent to a patient. A device includes a flow control member for placement in an air passageway communicating with a lung portion and when deployed in the air passageway inhibits a therapeutic agent distal of the control member from moving proximal of the control member, and includes the therapeutic agent associated with the flow control member. The control member may inhibit movement of the therapeutic agent by limiting airflow, and may include a one-way valve limiting exhalation of air from the lung portion. The control member may include a flexible membrane impervious to air flow, or a separator arranged to inhibit the movement of the therapeutic agent. The control member may include at least one anchor, and the anchor may be releasable from the air passageway for removal of the intra-bronchial device.

Abstract: The present invention includes an intra-bronchial device, system, and method for providing a therapeutic agent to a patient. A device includes a flow control member for placement in an air passageway communicating with a lung portion, and when deployed in the air passageway inhibits a therapeutic agent distal of the control member from moving proximal of the control member, and includes the therapeutic agent associated with the flow control member. The control member may inhibit movement of the therapeutic agent by limiting airflow, and may include a one-way valve limiting exhalation of air from the lung portion. The control member may include a flexible membrane impervious to air flow, or a separator arranged to inhibit the movement of the therapeutic agent. The control member may include at least one anchor, and the anchor may be releasable from the air passageway for removal of the intra-bronchial device.

Abstract: An implantable fluid separator having a housing holding a membrane which allows fluid to pass through. The fluid is drained from the housing and removed from the body.

Abstract: The present invention includes an intra-bronchial device, system, and method for providing a therapeutic agent to a patient. A device includes a flow control member for placement in an air passageway communicating with a lung portion, and when deployed in the air passageway inhibits a therapeutic agent distal of the control member from moving proximal of the control member, and includes the therapeutic agent associated with the flow control member. The control member may inhibit movement of the therapeutic agent by limiting airflow, and may include a one-way valve limiting exhalation of air from the lung portion. The control member may include a flexible membrane impervious to air flow, or a separator arranged to inhibit the movement of the therapeutic agent. The control member may include at least one anchor, and the anchor may be releasable from the air passageway for removal of the intra-bronchial device.

Abstract: Implanted catheters are locked with a solution comprising a lower alcohol, typically ethanol, propanol, or butanol, most preferably isopropanol, and an additive, the additive comprising an anti-microbial, typically taurolidine or triclosan, or an anti-coagulant, typically riboflavin, sodium citrate, ethylene diamine tetraacetic acid, or citric acid. The use of an alcohol and additive solution can effectively reduce fouling of the catheter, particularly clotting and thrombus in intravascular catheters, as well as reduce the risk of infection. The risk of infection can be further reduced by employing a catheter body which is sufficiently porous to permit the anti-microbial solution of a lower alcohol and another anti-microbial or anti-coagulant compound to penetrate into the catheter body and preferably through the catheter into tissue surrounding the implanted catheter.

Abstract: An intra-bronchial device provides a medicant intra-bronchially. The medicant may be used for controlling biological interaction of an intra-bronchial obstruction device with the patient, to treat a disease or condition of the lungs such as pneumonia or lung cancer, or to treat a systemic disease or condition. The medicant is provided by associating a medicant with the intra-bronchial device, either before, at the time of placement, or after placement. The medicant may overlie at least a portion of the intra-bronchial device, be absorbed into at least a portion of the intra-bronchial device, or be carried in a chamber. The intra-bronchial device may further include an absorptive member, and the medicant is absorbed by the absorptive member.

Abstract: The present invention includes an intra-bronchial device, system, and method for providing a therapeutic agent to a patient. A device includes a flow control member for placement in an air passageway communicating with a lung portion, and when deployed in the air passageway inhibits a therapeutic agent distal of the control member from moving proximal of the control member, and includes the therapeutic agent associated with the flow control member. The control member may inhibit movement of the therapeutic agent by limiting airflow, and may include a one-way valve limiting exhalation of air from the lung portion. The control member may include a flexible membrane impervious to air flow, or a separator arranged to inhibit the movement of the therapeutic agent. The control member may include at least one anchor, and the anchor may be releasable from the air passageway for removal of the intra-bronchial device.

Abstract: Implanted catheters are locked with a solution comprising a lower alcohol, typically ethanol, propanol, or butanol, most preferably isopropanol. The use of an alcohol can both reduce fouling of the catheter, particularly clotting and thrombus in intravascular catheters, as well as reducing the risk of infection. The risk of infection can be further reduced by employing a catheter body which is sufficiently porous to permit the lower alcohol or other anti-microbial solution to penetrate into the catheter body and preferably through the catheter into tissue surrounding the implanted catheter.

Abstract: Implantable ports and other devices are cleansed by the injection of a washing solution into a region in the device or in a tissue pocket surrounding the device. In a first embodiment, the washing solution is injected through an aperture in the device to flush internal regions of the device before infusing the tissue pocket and flushing outwardly through a tissue tract leading to the device. In other embodiments, the washing solution is injected directly to a target site on the exterior of the device. Implantable devices may include special, usually hardened, target regions for receiving the sharpened end of a needle used to inject the washing solution. Kits will include devices, syringes, access devices, and instructions for cleansing according to the methods of the present invention.

Abstract: The present invention provides an intra-bronchial device and method that controls biological interaction of the device with the patient. The intra-bronchial device is adapted to be placed in an air passageway of a patient to collapse a lung portion associated with the air passageway. The device includes an obstructing member that prevents air from being inhaled into the lung portion to collapse the lung portion, and a medicant carried by the obstructing member. The medicant may overlie at least a portion of the obstructing member, or the medicant may be absorbed in at least a portion of the obstructing member. The obstructing member may further include an absorptive member, and the medicant is absorbed by the absorptive member.

Abstract: Implantable ports and other devices are disinfected by the injection of an anti-microbial agent into a region in the device or in a tissue pocket surrounding the device. In a first embodiment, the anti-microbial agent is injected through an aperture in the device to flush internal regions of the device before infusing the tissue pocket and flushing outwardly through a tissue tract leading to the device. In other embodiments, the anti-microbial agent is injected directly to a target site on the exterior of the device. Implantable devices may include special, usually hardened, target regions for receiving the sharpened end of a needle used to inject the anti-microbial agent. Kits will include devices, syringes, access devices, and instructions for disinfection according to the methods of the present invention.

Abstract: Implanted catheters are locked with a solution comprising a lower alcohol, typically ethanol, propanol, or butanol, most preferably isopropanol. The use of an alcohol can both reduce fouling of the catheter, particularly clotting and thrombus in intravascular catheters, as well as reducing the risk of infection. The risk of infection can be further reduced by employing a catheter body which is sufficiently porous to permit the lower alcohol or other anti-microbial solution to penetrate into the catheter body and preferably through the catheter into tissue surrounding the implanted catheter.

Abstract: Implantable ports and other devices are cleansed by the injection of a washing solution into a region in the device or in a tissue pocket surrounding the device. In a first embodiment, the washing solution is injected through an aperture in the device to flush internal regions of the device before infusing the tissue pocket and flushing outwardly through a tissue tract leading to the device. In other embodiments, the washing solution is injected directly to a target site on the exterior of the device. Implantable devices may include special, usually hardened, target regions for receiving the sharpened end of a needle used to inject the washing solution. Kits will include devices, syringes, access devices, and instructions for cleansing according to the methods of the present invention.

Abstract: Implantable ports and other devices are cleansed by the injection of a washing solution into a region in the device or in a tissue pocket surrounding the device. In a first embodiment, the washing solution is injected through an aperture in the device to flush internal regions of the device before infusing the tissue pocket and flushing outwardly through a tissue tract leading to the device. In other embodiments, the washing solution is injected directly to a target site on the exterior of the device. Implantable devices may include special, usually hardened, target regions for receiving the sharpened end of a needle used to inject the washing solution. Kits will include devices, syringes, access devices, and instructions for cleansing according to the methods of the present invention.

Abstract: Implantable ports and other devices are disinfected by the injection of an anti-microbial agent into a tissue pocket surrounding the device. In a first embodiment, the anti-microbial agent is injected through an aperture in the device to flush internal regions of the device before infusing the tissue pocket. In other embodiments, the anti-microbial agent is injected directly to a target site on the exterior of the device. Implantable devices may include special, usually hardened, target regions for receiving the sharpened end of a needle used to inject the anti-microbial agent.

Abstract: Systems for draining retained body fluids comprise an implantable port in an access tube. Usually, a drainage cannula for connecting the implantable port to a site of fluid retention is also provided. The implantable port and drainage cannula are implanted subcutaneously with one end of the cannula within the site of fluid retention and the port located remotely from such site. Drainage may then be effected by percutaneously introducing the access tube to the port and optionally applying a vacuum. Kits comprise the implantable port together with instructions for implanting the port as described above. Kits also comprise an access tube with instructions for use for accessing an implanted port as described above.

Abstract: A catheter with valve for implantation in a vascular structure of a living being. The catheter is in the general shape of a "T" with the top of the "T" implanted within the lumen of or anastomotically attached to a vascular structure. The lumen of the implanted portion of the catheter completely occupies or may be aligned with the lumen of the vascular structure, causing all blood flow through the vascular structure to be directed through the implanted portion of the catheter. A valve is placed in the wall of the implanted portion of the catheter which opens into the lumen of the leg of the "T" of the catheter upon application of sufficient differential pressure between the lumens of the two portions of the catheter. The leg of the "T" may be connected to the side wall of the implant portion of the catheter at an angle, such that the axis of the lumen of the leg of the "T" intersects the axis of the lumen of the implanted portion of the catheter at approximately a 45.degree. angle.

Abstract: Nozzle cooling and wall contact prevention control are included in a gaseous CRISLA apparatus, along with removable collectors, and the efficient use of one or more currently available high power lasers to produce a commercially economic isotope separation process. The wall contact prevention is accomplished with gaseous boundary layers, and a supersonic nozzle normally is used to cool and separate excitation bands of the isotopic material. Non-intermixing gaseous streams with different isotopic assays can be created in a single nozzle chamber and segmented collection chamber, which along with recirculation loops and compressors, allows a single laser system and a single nozzle system to be used to selectively excite the isotopic material while it makes multiple passes through the laser beams of the laser system until only a small fraction of the desired isotope remains to be separated. The process is especially effective in separating .sup.235 UF.sub.6 from a gaseous mixture of .sup.235 UF.sub.6 and .sup.